<DOC>
	<DOCNO>NCT02352896</DOCNO>
	<brief_summary>EPI-743 Leigh syndrome subject participate previous EPI743-12-002 study .</brief_summary>
	<brief_title>Long-Term Safety Efficacy Evaluation EPI-743 Children With Leigh Syndrome</brief_title>
	<detailed_description>To monitor long-term safety neurodevelopmental effect EPI-743 child complete EPI743-12-002 placebo control trial .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leigh Disease</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>1 . Diagnosis Leigh syndrome genetic confirmation 2 . Completion EPI74312002 protocol initiation treatment within 14 day Month 12 Visit EPI74312002 study 3 . Patient Patient 's guardian able consent comply protocol requirement 4 . Continued abstention supplement exclude EPI74312002 study 5 . Continued abstention BotoxÂ® duration study 1 . Allergy EPI743 sesame oil 2 . Allergy vitamin E 3 . Clinical history bleed abnormal baseline PT/PTT 4 . Hepatic insufficiency LFTs great two time upper limit normal 5 . Renal insufficiency require dialysis 6 . End stage cardiac failure 7 . Fat malabsorption syndrome preclude drug absorption 8 . Use anticoagulant medication 9 . Participation clinical research studies/taking experimental agent 10 . Participation elective procedure require sedation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Leigh syndrome</keyword>
	<keyword>Mitochondrial disorder</keyword>
	<keyword>EPI743</keyword>
	<keyword>Vincerinone</keyword>
</DOC>